{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-028437","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.619860+00:00","generated_at":"2026-06-21T09:29:19.226150+00:00","sec_items":["1.02","1.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Patheon terminates manufacturing agreement with AcelRx; effective May 31, 2024","bullets":["Patheon provided notice on Nov 29, 2022 to terminate the MSA, originally dated Dec 12, 2012.","MSA termination effective May 31, 2024; Patheon to continue supplying product until then.","Capital Equipment Agreement between parties likewise terminates upon MSA termination.","AcelRx expects to discuss a transition plan with Patheon in the near future."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-028437","json":"https://secwatch.observer/filing/0001437749-22-028437.json","markdown":"https://secwatch.observer/filing/0001437749-22-028437.md","text":"https://secwatch.observer/filing/0001437749-22-028437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922028437/0001437749-22-028437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922028437/acrx20221204_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:29:19.226150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8127c44f619aec5baee6d602daddb3abf539ade4","claim":"TALPHERA, INC. terminated MSA with Patheon Pharmaceuticals Inc. (effective 2024-05-31).","evidence_excerpt":"On November 29, 2022, AcelRx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received notice from Patheon Pharmaceuticals Inc. (“Patheon”) that it intends to terminate the Manufacturing Services Agreement between the parties, effective December 12, 2012, as amended January 19, 2016 and August 4, 2017 (collectively, the “MSA”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922028437/0001437749-22-028437-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Patheon Pharmaceuticals Inc."},{"label":"Effective","value":"2024-05-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}